Gastric Cancer Therapeutics Market to Grow with a CAGR of 13.99% through 2031

Rising cases of stomach cancer to drive the growth of Global Gastric Cancer Therapeutics Market, in the forecast period, 2027-2031.

According to TechSci Research report, “Global Gastric Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), By Molecule Type (Small Molecule, Biologics), By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy), By Mode of Action (Programmed Cell Death Protein 1 Inhibitors, Human Epidermal Growth Factor Receptor Antagonists, Vascular Endothelial Growth Factor Receptor Antagonists, Others), By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2031”, the Global Digital X-ray Systems Market will grow from USD 4.41 Billion in 2025 to USD 6.45 Billion by 2031 at a 6.54% CAGR. The global gastric cancer therapeutics market is poised for significant expansion over the coming years, driven by the increasing incidence of gastric adenocarcinoma, particularly in regions like East Asia, Eastern Europe, and parts of Latin America. Stomach cancer remains one of the most prevalent and deadly malignancies globally, often diagnosed at advanced stages due to the absence of early symptoms and limited access to early screening methods. The growing patient pool, coupled with ongoing advancements in targeted therapies, immunotherapy, and precision oncology, is fueling the development of more effective treatment approaches.

Gastric cancer primarily develops from the glandular cells lining the stomach, most commonly presenting as adenocarcinoma. Risk factors such as Helicobacter pylori infection, smoking, high salt intake, poor diet, and genetic predisposition significantly contribute to disease onset. Patients often exhibit symptoms including persistent indigestion, bloating, heartburn, and a sense of fullness after small meals leading to delayed diagnosis in many cases. The unmet need for curative therapies has prompted pharmaceutical and biotech companies to intensify research aimed at developing drugs with higher efficacy and reduced recurrence risks.

Recent therapeutic innovations are transforming treatment landscapes. Immunotherapies targeting PD-1 and PD-L1 pathways, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have shown encouraging clinical outcomes in advanced gastric cancer by extending survival rates and improving tumor response. Additionally, HER2-targeted therapies like trastuzumab (Herceptin) and newer agents such as trastuzumab deruxtecan (Enhertu) are reshaping personalized treatment paradigms for HER2-positive patients. Emerging therapeutic candidates include FGFR2b and CLDN18.2 inhibitors (such as bemarituzumab and zolbetuximab), which are currently in late-stage clinical trials and have demonstrated promising results in metastatic gastric cancer subsets. Combination regimens incorporating immunotherapy with chemotherapy or targeted drugs are also gaining prominence, providing synergistic effectiveness and delaying disease progression.

Beyond drug innovation, expanding diagnostic capabilities such as molecular testing, next-generation sequencing (NGS), and liquid biopsy are enabling oncologists to identify actionable genetic mutations early and tailor therapy accordingly. Growing use of precision medicine and biomarker-based treatment segmentation is expected to improve prognosis for gastric cancer patients in the near future.

The post-COVID-19 recovery of healthcare infrastructure, expansion of cancer screening programs, and increased government and private funding for oncology research are further boosting the market. Key industry players including F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, AstraZeneca Plc, Merck & Co., Eli Lilly and Company, Amgen Inc., BeiGene Ltd., Daiichi Sankyo Company Ltd., and Pfizer Inc. are actively engaged in developing advanced therapeutics across the value chain—from monoclonal antibodies to novel small molecules and combination therapies. Collaborations between pharmaceutical firms and research institutions are accelerating the discovery of next-generation treatment modalities aimed at overcoming resistance mechanisms and enhancing long-term efficacy.

Overall, the global gastric cancer therapeutics market is evolving rapidly as scientific innovation converges with rising disease burden and advancing clinical research. Though a definitive cure remains elusive, sustained progress in targeted and immune-oncology therapies, coupled with precision diagnostics and early intervention strategies, is expected to drastically improve survival outcomes and reshape the treatment landscape for gastric cancer patients worldwide..

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on " Global Gastric Cancer Therapeutics Market"

https://www.techsciresearch.com/report/gastric-cancer-therapeutics-market/7403.html

The global gastric cancer therapeutics market is segmented on the basis of therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitive landscape, and regional distribution. Based on disease indication the market is further segmented into gastric adenocarcinoma, gastrointestinal stromal tumor (GIST), gastric neuroendocrine tumors (gNET). Gastric adenocarcinoma is anticipated to assert its dominance over the market owing to the fact that it is the most common form of the gastric cancer, worldwide. Unhealthy diet, obesity cases, growing geriatric population of the world is further anticipated to stimulate the growth of the global gastric cancer therapeutics market in the next five years.

Based on molecule type the market is further segmented into small molecules and biologics. Small molecules and biologics are a type of therapeutic drugs that are incorporated to treat the symptoms of stomach/ gastric cancer. Various small molecule drugs are region specifically efficient. For example, Apatinib is the first-discovered small molecule inhibitor for VEGFR tyrosine kinase that has a clear effect on Asian patients with advanced gastric cancer. Whereas biologics are more focused and are utilized as targeted drugs for a wider circle of patient. Thus, efficiency of the biologics is anticipated to drive the segment growth of biologics to a significant growth such that it is expected to hold the largest share of the market in the next five years until 2026.

Some of the major competitors in the market are Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc., among others.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7403

Customers can also request for 10% free customization on this report.

“New market players who are potential pipeline candidates for the research and development activities to develop the targeted therapies that have an efficiency to treat gastric cancer can benefit from these endeavors. Targeted therapies would involve special drugs, that affects the growth of the carcinogenic cells. Moreover, chemotherapy and radiotherapy has proven itself to be effective thereby new players are advised to find more efficient chemotherapy and radiotherapy options. North America is a tentatively dominant market sector owing to its world-class healthcare industry that is developed and is efficient towards finding the cure to cancer through its excellent team for research and development,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Gastric Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), By Molecule Type (Small Molecule, Biologics), By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy) By Mode of Action (Programmed Cell Death Protein 1 Inhibitors, Human Epidermal Growth Factor Receptor Antagonists, Vascular Endothelial Growth Factor Receptor Antagonists, Others), By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2021-2031F”, has evaluated the future growth potential of global Gastric Cancer Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Gastric Cancer Therapeutics. Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/